InsiderTrades.com logo

SXTP Insider Trading

Insider Ownership Percentage: 1.69%
Insider Buying (Last 12 Months): $91,366.35
Insider Selling (Last 12 Months): $0.00

60 Degrees Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at 60 Degrees Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

60 Degrees Pharmaceuticals Share Price & Price History

Current Price: $0.98
Price Change: ▼ Price Decrease of -0.0399 (-3.91%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for SXTP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

60 Degrees Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2025Cheryl XuDirectorBuy5,000$2.88$14,400.0015,816View SEC Filing Icon  
12/16/2024Cheryl XuDirectorBuy400$7.25$2,900.0010,815View SEC Filing Icon  
12/12/2024Cheryl XuDirectorBuy1,000$9.10$9,100.009,215View SEC Filing Icon  
12/9/2024Geoffrey S DowCEOBuy7,164$6.35$45,491.4018,916View SEC Filing Icon  
12/5/2024Geoffrey S DowCEOBuy3,509$5.55$19,474.957,635View SEC Filing Icon  
11/21/2024Geoffrey S DowCEOBuy700$4.55$3,185.004,125View SEC Filing Icon  
11/19/2024Geoffrey S DowCEOBuy500$4.50$2,250.003,225View SEC Filing Icon  
8/27/2024Cheryl XuDirectorBuy1,000$8.50$8,500.008,215View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

7.96% of 60 Degrees Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

60 Degrees Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
7/19/2024Central Bank & Trust Co.167,000$42K0.0%-37.7%1.368%Search for SEC Filing on Google Icon
4/11/2024Central Bank & Trust Co.268,000$70K0.0%-24.9%4.613%Search for SEC Filing on Google Icon
1/9/2024Central Bank & Trust Co.357,000$0.36M0.1%-23.7%6.155%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
60 Degrees Pharmaceuticals logo
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Read More on 60 Degrees Pharmaceuticals

Today's Range

Now: $0.98
Low: $0.96
High: $1.04

50 Day Range

MA: $1.31
Low: $0.91
High: $1.80

52 Week Range

Now: $0.98
Low: $0.85
High: $12.45

Volume

74,140 shs

Average Volume

51,705 shs

Market Capitalization

$4.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82

Who are the company insiders with the largest holdings of 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals' top insider investors include:
  1. Geoffrey S Dow (CEO)
  2. Cheryl Xu (Director)
Learn More about top insider investors at 60 Degrees Pharmaceuticals.